FDA Grants Orphan Drug Status to WAVE’s Huntington’s Disease Drug Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to WAVE Life Sciences‘ lead candidate WVE-120101, which is being developed for the treatment of Huntington’s disease (HD). “Each potential new therapy for Huntington’s disease gives fresh hope to the more than 30,000 Americans symptomatic with HD and…